Hereditary ovarian cancer in Poland.

scientific article published in October 2003

Hereditary ovarian cancer in Poland. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/IJC.11338
P698PubMed publication ID12918074

P50authorOlga HausQ11797861
Jan LubińskiQ11718282
Izabella Rzepka-GórskaQ114456255
Helena ZientekQ117235135
Stanisław GóźdźQ18590952
Jerzy Roman KowalczykQ21328387
Steven A. NarodQ50384888
Anna JakubowskaQ58323317
Marek BebenekQ114333817
Malgorzata Stawicka-NielacnaQ114456213
Marek SzwiecQ114456232
Hanna JaniszewskaQ114456244
Dariusz GodlewskiQ114456246
Małgorzata Foszczyńska-KłodaQ114456248
Izabela BrozekQ114456249
Beata Kozak-KlonowskaQ114456250
Roman MiturskiQ114456251
Stanisław NiepsujQ114456252
Bernard WaśkoQ114456253
Andrzej RozmiarekQ114456254
Tomasz ByrskiQ58345332
Janusz MenkiszakQ58898660
Ewa GrzybowskaQ62589470
Andrzej MackiewiczQ89457664
Jacek GronwaldQ91084015
Tomasz HuzarskiQ97187823
Bohdan GórskiQ98618546
P2093author name stringKrzysztof Urbański
Katarzyna Lamperska
Magdalena Perkowska
Jan Koc
Kazimierz Drosik
Anna Pluzańska
Elwira Strózyk
P2860cites workFounder mutations in the BRCA1 gene in Polish families with breast-ovarian cancerQ24540270
Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in PakistanQ24611839
Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family historyQ33869223
Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in HungaryQ33900686
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancerQ34113283
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutationQ34129784
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutationsQ34129787
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancerQ34145544
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersQ34162534
Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutationsQ40718941
BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristicsQ44060672
BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patientsQ44969666
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study GroupQ47701078
Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutationQ48070015
Genetic epidemiology of BRCA1 mutations in Norway.Q53145195
High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer.Q55034444
Contribution of BRCA1 mutations to ovarian cancerQ73215230
Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern PolandQ73734735
Clinicopathologic features of BRCA-linked and sporadic ovarian cancerQ73782102
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control studyQ73936350
BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testingQ74525381
Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. OnlineQ78125794
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectPolandQ36
ovarian cancerQ172341
P304page(s)942-945
P577publication date2003-10-01
P1433published inInternational Journal of CancerQ332492
P1476titleHereditary ovarian cancer in Poland
P478volume106

Reverse relations

cites work (P2860)
Q89999716A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy
Q34548008A high proportion of founder BRCA1 mutations in Polish breast cancer families
Q33722598BRCA1 4153delA founder mutation in Russian ovarian cancer patients
Q53506544BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients.
Q44221699BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Q34185187BRCA1 founder mutations compared to ovarian cancer in Belarus
Q37327095BRCA1 testing
Q37011738Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations
Q36930042Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status
Q36446316Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients
Q91639244Current Genetic Service Delivery Models for the Provision of Genetic Testing in Europe: A Systematic Review of the Literature
Q36903256Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases
Q40821559Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?
Q38609944Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation
Q37720438Epidemiology of ovarian cancer: a review
Q36117690Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
Q57579994Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia
Q50320232Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland.
Q92354777Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome
Q35060014Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
Q34059765Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia
Q93032475Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study
Q33458308Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor
Q35944416Hereditary breast-ovarian cancer syndrome in Russia.
Q37147699High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
Q81587439High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland
Q36474986High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing
Q43522641High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia
Q35828679Improved survival in BRCA2 carriers with ovarian cancer
Q37123377Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing
Q84817507Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers
Q38221583Multiple primary cancers as a guide to heritability
Q35546258Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing
Q34705352On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations
Q79772653PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations
Q39958494Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer
Q37697025Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry
Q50849096Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine.
Q33584095The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome
Q26741851The biological effects and clinical implications of BRCA mutations: where do we go from here?
Q37453854The contribution of BRCA1 and BRCA2 to ovarian cancer
Q38809495The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania

Search more.